Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
Year: 2025
Type: article
Source: Annals of Oncology
Institutions: Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Hospital Universitario de Torrejón, MedSIR (Spain), Universidad Europea de Madrid, Memorial Sloan Kettering Cancer Center, Asan Medical Center, University of Ulsan, Sarah Cannon, University of Washington, Fred Hutch Cancer Center, Yale Cancer Center, University of Milan, European Institute of Oncology, Nagoya City University, Seoul National University, Seoul National University Hospital, AstraZeneca (United States), Daiichi Sankyo (United States), Université Paris-Saclay, Institut Gustave Roussy
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: Pfizer, Gilead Sciences, Daiichi-Sankyo
OpenAlex ID: W4416414136